Pasar al contenido principal

REPROGRAMACION METABOLICA EN CELULAS TUMORALES

PI17/00412

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA
Centro realización FACULTAD DE MEDICINA (UCB)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD

  • Weber, Minéia
  • Mera, Paula|||0000-0001-8941-4637
  • Casas, Josefina|||0000-0002-7926-5209
  • Salvador, Javier
  • Rodríguez, Amaia|||0000-0002-2180-461X
  • Alonso Muñoz, Sergio|||0000-0002-3989-8757
  • Sebastián, David|||0000-0002-7260-3869
  • Soler Vázquez, M. Carmen|||0000-0003-1430-5617
  • Montironi, Carla|||0000-0002-1453-2193
  • Recalde, Sandra|||0000-0002-6174-0649
  • Fucho, Raquel|||0000-0002-1774-9099
  • Calderon-Dominguez, María|||0000-0003-1797-3450
  • Mir, Joan Francesc|||0000-0001-8501-0969
  • Bartrons, Ramon|||0000-0001-9349-5847
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Sánchez-Infantes, David|||0000-0001-6086-7501
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Casals, Nuria|||0000-0002-6719-4300
  • Valentí, Victor|||0000-0002-7074-2849
  • Frühbeck, Gema|||0000-0002-8305-7154
  • Herrero, Laura|||0000-0003-4244-4673
  • Serra, Dolors|||0000-0002-4936-4206
The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased drastically due to the global obesity pandemic but at present there are no approved therapies. Here, we aimed to revert high-fat diet (HFD)-induced obesity and NAFLD in mice by enhancing liver fatty acid oxidation (FAO). Moreover, we searched for potential new lipid biomarkers for monitoring liver steatosis in humans. We used adeno-associated virus (AAV) to deliver a permanently active mutant form of human carnitine palmitoyltransferase 1A (hCPT1AM), the key enzyme in FAO, in the liver of a mouse model of HFD-induced obesity and NAFLD. Expression of hCPT1AM enhanced hepatic FAO and autophagy, reduced liver steatosis, and improved glucose homeostasis. Lipidomic analysis in mice and humans before and after therapeutic interventions, such as hepatic AAV9-hCPT1AM administration and RYGB surgery, respectively, led to the identification of specific triacylglyceride (TAG) specie (C50:1) as a potential biomarker to monitor NAFFLD disease. To sum up, here we show for the first time that liver hCPT1AM gene therapy in a mouse model of established obesity, diabetes, and NAFLD can reduce HFD-induced derangements. Moreover, our study highlights TAG (C50:1) as a potential noninvasive biomarker that might be useful to monitor NAFLD in mice and humans.